natgillin/translations-raw huggingface dataset:
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the 
Pri odločanju o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi zdravljenja z zdravilom Altargo je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja z zdravilom Altargo za mater.
Keep using Altargo for as long as your doctor advises. 
Zdravilo Altargo uporabljajte tako dolgo, kot vam je svetoval zdravnik.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. .
The reason for the reduced clinical efficacy observed in 
Vzrok za manjšo klinično učinkovitost pri teh
Prolonged use and overgrowth of non-susceptible micro-organisms Prolonged use of retapamulin may result in overgrowth of non-susceptible micro-organisms, including fungi. 
Dolgotrajna uporaba in prekomerna rast neobčutljivih mikroorganizmov Dolgotrajna uporaba retapamulina lahko povzroči prekomerno rast neobčutljivih mikroorganizmov,
What Altargo is and what it is used for What you need to know before you use Altargo 
Kaj je zdravilo Altargo in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Altargo
No studies to evaluate effects of retapamulin on pre-/postnatal development were performed. 
Študije, ki bi ovrednotile vpliv retapamulina na pre-/postnatalni razvoj, niso bile izvedene.
Altargo is not expected to affect your ability to drive or use machines. 
Ni pričakovati, da bi zdravilo Altargo vplivalo na vašo sposobnost upravljanja vozil in strojev.
If the ointment accidentally gets on to these areas, wash the area with water and consult your doctor if you experience discomfort. 
Če mazilo po nesreči pride v stik s temi področji, področje sperite z vodo in se v primeru težav posvetujte s svojim zdravnikom.
What you need to know before you use Altargo 
Kaj morate vedeti, preden boste uporabili zdravilo Altargo
However, when adjusted for baseline wound characteristics including pathogen, wound size and severity, the clinical success rate of retapamulin was superior to placebo for the primary efficacy endpoint (p=0.0336). 
Po prilagoditvi na izhodiščne značilnosti rane, vključno s patogenom, velikostjo rane in resnostjo, je bila klinična uspešnost retampulina glede na primarno končno točko za učinkovitost superiorna v primerjavi s placebom (p = 0,0336).
What Altargo is and what it is used for 
Kaj je zdravilo Altargo in za kaj ga uporabljamo
Therefore the pleuromutilins appear to inhibit bacterial protein synthesis by multiple 
Zdi se, da pleuromutilini zavirajo sintezo bakterijskih proteinov na več načinov.
Apply the ointment as soon as you remember, and apply the next dose at the usual time. 
Naslednji odmerek nanesite ob običajnem času.
One involves mutations in ribosomal protein L3, the second is a non-specific efflux mechanism (ABC transporter vgaAv). 
Eden vključuje mutacije ribosomskega proteina L3, drugi pa nespecifični mehanizem prenosa (ABC-prenašalec vgaAv).
Do not stop using this medicine before talking to your doctor or pharmacist. 
Ne prenehajte uporabljati tega zdravila, ne da bi se pred tem posvetovali s svojim zdravnikom ali s farmacevtom.
However, in the two studies that enrolled patients with SIOW the efficacy of retapamulin in infections due to MRSA was inadequate (75.7%). 
V dveh študijah, ki sta vključevali bolnike s sekundarnimi okužbami odprtih ran, pa je bila učinkovitost retapamulina pri okužbah z MRSA nezadostna (75,7 %).
The following side effects have occurred on the skin where Altargo has been applied: Common side effects (may affect up to 1 in 10 people): 
Naslednji neželeni učinki so se pojavili na predelu kože, kjer je bilo naneseno zdravilo Altargo: Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 oseb):
Retapamulin is a semi-synthetic derivative of the compound pleuromutilin, which is isolated through fermentation from Clitopilus passeckerianus (formerly Pleurotus passeckerianus). 
Retapamulin je polsintetični derivat pleuromutilina, izoliranega pri fermentaciji glive Clitopilus passeckerianus (prej imenovane Pleurotus passeckerianus).
The explanation for lower clinical efficacy against MRSA in SIOW is unclear and it may have been influenced by the presence of a particular MRSA clone. 
Vzrok za manjšo klinično učinkovitost proti MRSA pri sekundarnih okužbah odprtih ran ni jasen in je lahko posledica prisotnosti določenega klona MRSA.
ITTC- Intent to Treat Clinical Primary Efficacy Population; PPC -Per Protocol Clinical Primary Efficacy population; ITTB- Intent to Treat Bacteriological evaluable, Primary Efficacy Population; PPB - Per Protocol Bacteriologically evaluable, Primary Efficacy Population. 
ITTC - populacija za primarno klinično učinkovitost, ki so jo nameravali zdraviti; PPC - populacija za primarno klinično učinkovitost, skladna s protokolom; ITTB - populacija za primarno klinično učinkovitost, ki so jo nameravali zdraviti in pri kateri je bila mogoča bakteriološka ocena; PPB - populacija za primarno klinično učinkovitost, skladna s protokolom, pri kateri je bila mogoče bakteriološka ocena.
Altargo is used to treat bacterial infections affecting small areas of skin. 
Zdravilo Altargo uporabljamo za zdravljenje bakterijskih okužb na manjših predelih kože.
The study failed to meet the primary end point which was the clinical success rate at follow-up (day 12 - 14) for subjects in the Intent to Treat Clinical 
Študija ni dosegla primarne končne točke, ki je bila delež klinične uspešnosti med spremljanjem (od 12. do 14. dneva) pri preizkušancih v skupini, ki so jo nameravali zdraviti (glejte spodnjo tabelo).
Application site irritation (including burning sensation) 
Draženje na mestu uporabe (vključno s pekočim občutkom)
The majority of samples (89%) were below the lower limit of quantitation (0.5 ng/ml). 
Večina vzorcev (89 %) je bila pod mejo dokazljivosti (0,5 ng/ml).
Carcinogenesis, mutagenesis, reproductive toxicity Long-term studies in animals to evaluate carcinogenic potential have not been conducted with 
Kancerogenost, mutagenost in vpliv na sposobnost razmnoževanja Dolgotrajne študije, ki bi ovrednotile kancerogeni potencial retapamulina, na živalih niso bile
Data indicate that the binding site involves ribosomal protein L3 and is in the region of the ribosomal P site and peptidyl transferase centre. 
Podatki kažejo, da vezavno mesto obsega ribosomski protein L3 in je na področju ribosomskega P mesta in centra za peptidiltransferazo.
However by the Follow-up visit this difference was less pronounced, (88.6% vs, 81% for retapamulin and placebo treated subjects respectively). 
Pri obisku za spremljanje pa je bila ta razlika manj očitna (88,6 % pri preizkušancih z retapamulinom in 81 % pri
For S. aureus isolates with laboratorygenerated mutations in ribosomal protein L3, retapamulin MICs were 0.25-4 µg/ml. 
Pri izolatih S. aureus, ki so imeli laboratorijsko ustvarjene mutacije ribosomske beljakovine L3, je bila MIC retapamulina od 0,25 do 4 µg/ml.
If there is no improvement in your infection after two to three days of treatment contact your doctor. 
Če po dveh do treh dneh ne opazite izboljšanja okužbe, se posvetujte s svojim zdravnikom.
Due to its distinct mode of action, target specific cross-resistance with other classes of antibacterial agents is rare. 
Zaradi posebnega načina delovanja je ciljno specifična navzkrižna odpornost z drugimi skupinami
It is supplied in an aluminium tube with a plastic cap, containing either 5, 10 or 15 grams of ointment, or in an aluminium foil sachet containing 0.5 g of ointment. 
Na voljo je v aluminijastih tubah s plastično zaporko, ki vsebujejo 5, 10 ali 15 gramov mazila ali v vrečicah iz aluminijaste folije, ki vsebujejo 0,5 g mazila.
It is unknown whether retapamulin is excreted in human breast milk. 
Ni znano, če se retapamulin izloča z materinim mlekom.
The in vitro oxidative metabolism of retapamulin in human liver microsomes was primarily mediated by CYP3A4 with minor contributions from CYP2C8 and CYP2D6 (see section 4.5). 
Oksidativna presnova retapamulina v človeških jetrnih mikrosomih je bila in vitro v glavnem povezana s CYP3A4 in le v manjši meri s CYP2C8 in CYP2D6 (glejte poglavje 4.5).
This difference was primarily due to the higher success rate observed in retapamulin-treated subjects with infections caused by S. aureus in comparison to placebo treated subjects (see Table below). 
Ta razlika je bila predvsem posledica večjega deleža uspešnosti, ki so ga opazili pri preizkušancih, ki so jih zdravili z retapamulinom in so imeli okužbe s S. aureus, v primerjavi s preizkušanci, ki so prejemali placebo (glejte spodnjo tabelo).
In the Intent to Treat Bacteriological evaluable population, the clinical success rate of retapamulin (76.4%: 139/182) was statistically superior to that of placebo (64.3%; 54/84). 
Pri populaciji, ki so jo nameravali zdraviti in pri kateri je bila mogoča bakteriološka ocena, je bil delež klinične uspešnosti retapamulina (76,4 %: 139/182) statistično superioren v primerjavi s placebom (64,3 %; 54/84).
Placebo n/N Success rate (%) 
Placebo n/N Delež uspešnosti
Glaxo Operations UK Ltd. (trdg as Glaxo Wellcome Operations) Harmire Road 
Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations) Harmire Road
Do not use in the eyes or on mucous membranes. 
Ne uporabljajte na očeh ali sluznicah.
There are no data on the effects of retapamulin on human fertility. 
Podatkov o vplivu retapamulina na plodnost pri človeku ni.
It is possible that using Altargo in children who are taking certain medicines (such as some medicines used to treat fungal infections) could result in blood concentrations of Altargo that are higher than usual. 
Pri otrocih, ki dobivajo določena zdravila (npr. nekatera zdravila za zdravljenje glivičnih okužb), bi uporaba zdravila Altargo lahko povzročila večjo koncentracijo zdravila Altargo v krvi, kot je običajno.To bi lahko povzročilo neželene učinke.
Therefore it is not expected that clinically important increases in plasma concentrations of retapamulin will occur in patients aged 2 years and older who are also receiving CYP3A4 inhibitors. 
Zato ni pričakovati, da bi se koncentracija retapamulina v plazmi klinično pomembno povečala pri bolnikih, starih 2 leti ali več, ki dobivajo tudi zaviralce CYP3A4.
• Infected small lacerations, abrasions, or sutured wounds. 
 okužene manjše raztrganine, odrgnine ali zašite rane.
This plasma concentration was observed in a child with a secondary infected dermatosis, for which retapamulin is not indicated 
To koncentracijo v plazmi so izmerili pri otroku s sekundarno okuženo dermatozo, pri katerih uporaba retapamulina ni indicirana.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not use in the eyes or on mucous membranes. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Ne uporabljajte na očeh ali sluznicah.
Retapamulin should not be used to treat abscesses. 
Retapamulina se ne sme uporabljati za zdravljenje abscesov.
Retapamulin is predominantly bacteriostatic against S. aureus and S. pyogenes. 
Retapamulin deluje pretežno bakteriostatično proti S. aureus in S. pyogenes.
Altargo should not be used on children who are less than nine months old. 
Zdravila Altargo se ne sme uporabljati pri otrocih, mlajših od devet mesecev.
See section 5.2 regarding plasma concentrations of retapamulin observed in patients in different age groups. 
Glejte poglavje 5.2 glede koncentracije retapamulina v plazmi pri bolnikih v različnih starostnih
Nevertheless, the highest plasma concentrations recorded were low (< 10.5 ng/ml in the absence of ketoconazole and < 17 ng/ml in the presence of ketoconazole. 
Kljub temu je bila največja zabeležena koncentracija v plazmi majhna (≤10,5 ng/ml v odsotnosti ketokonazola in ≤17 ng/ml v prisotnosti ketokonazola).
Altargo ointment contains an antibiotic called retapamulin, which is used on the skin. 
Zdravilo Altargo mazilo vsebuje antibiotik retapamulin, ki se uporablja na koži.
Due to the very low systemic exposures, tissue distribution of retapamulin has not been investigated in humans. 
Zaradi zelo majhne sistemske izpostavljenosti pri človeku porazdelitve retapamulina v tkiva niso raziskovali.
Retapamulin ointment should only be used in pregnancy when topical antibacterial therapy is clearly indicated and the use of retapamulin is considered to be preferable to administration of a systemic antibacterial medicinal product. 
Mazilo z retapamulinom se sme med nosečnostjo uporabljati le, če je lokalno zdravljenje s protibakterijskim zdravilom nujno potrebno in uporaba retapamulina primernejša od sistemskega zdravljenja s protibakterijskim zdravilom.
Retapamulin is approximately 94% bound to human plasma proteins. 
Vezava retapamulina na plazemske proteine je približno 94-odstotna.
Lesions of subjects treated with retapamulin healed more quickly by the End of therapy visit (day 7-9), with a reduction in size of the lesions by 77.3% compared to 43.5% for placebo treated subjects. 
Lezije preizkušancev, ki so jih zdravili z retapamulinom, so se do zadnjega obiska med zdravljenjem (od 7. do 9. dneva) zacelile hitreje, pri čemer se je velikost lezij zmanjšala za 77,3 %, pri preizkušancih, ki so prejemali placebo, pa za 43,5 %.
A multicentre, randomised, double-blind, study compared the efficacy of retapamulin ointment to placebo ointment for the treatment of SIOW. 
Multicentrična, randomizirana, dvojno slepa študija je primerjala učinkovitost mazila z retapamulinom in mazila s placebom pri zdravljenju sekundarnih okužb odprtih ran.
Infections that may be treated include impetigo (which causes crusting scabs on infected areas), cuts, grazes and stitched wounds. 
Okužbe, ki se lahko zdravijo, so impetigo (pri katerem na okuženih predelih nastanejo skorjaste kraste) in okužene vreznine, odrgnine ali vbodne rane.
Each gram of ointment contains up to 20 micrograms of butylated hydroxytoluene (E321). 
En gram mazila vsebuje do 20 mikrogramov butilhidroksitoluena (E321).
There was no evidence of genotoxicity when evaluated in vitro for gene mutation and/or chromosomal effects in the mouse lymphoma cell assay, in cultured human peripheral blood lymphocytes, or when evaluated in vivo for chromosomal effects in a rat micronucleus test. 
Pri in vitro vrednotenju genske mutacije in/ali vplivov na kromosome pri testih na celicah mišjega limfoma, kulturi človeških limfocitov iz periferne krvi in pri in vivo vrednotenju vplivov na kromosome pri mikronukleus testih na podganah niso opazili znakov genotoksičnosti.
Retapamulin is for cutaneous use only. 
Retapamulin je namenjen samo za dermalno uporabo.
Susceptibility to pleuromutilins can also be affected by the Cfr rRNA methyltransferase, which confers cross-resistance to phenicols, lincosamides and streptogramin A in staphylococci. 
Občutljivost za pleuromutiline lahko poslabša tudi Cfr-rRNA-metiltransferaza, ki povzroča navzkrižno odpornost proti fenikolom, linkozamidom in streptograminu A pri stafilokokih.
Altargo is for adults and children aged nine months and older. 
Zdravilo Altargo lahko uporabljajo odrasli in otroci, stari devet mesecev in več.
In the case of treatment failure associated with S. aureus, the presence of strains possessing additional virulence factors (such as PantonValentine Leukocidin) should be considered. 
V primeru neuspešnega zdravljenja okužbe s S. aureus je treba presoditi o prisotnosti sevov z dodatnimi virulenčnimi faktorji (kot je Panton
Animal studies have shown reproductive toxicity after oral administration and are insufficient with respect to effects on parturition and fetal/postnatal development (see section 5.3). 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja po peroralni uporabi in niso zadostne za oceno vplivov na porod in razvoj zarodka ali postnatalni razvoj (glejte poglavje 5.3).
In vitro, retapamulin was shown to be a P-glycoprotein (Pgp) substrate and inhibitor. 
In vitro je bilo dokazano, da je retapamulin substrat za P-glikoprotein (Pgp) in njegov zaviralec.
This non-target specific efflux mechanism has also been demonstrated to reduce the in vitro activity of streptogramin A. 
Dokazano je bilo, da ta ciljno nespecifični mehanizem prenosa zmanjša tudi in vitro aktivnost
Your doctor will decide if Altargo can be used for a child aged less than 2 years old who is taking other medicines. 
Zdravnik bo presodil, ali lahko zdravilo Altargo dobi otrok, ki je mlajši od dveh let in
Retapamulin concentrations were measurable in 46% (36/79) of samples (range 0.52 to 177.3 ng/ml) but the majority of these samples (27/36; 75%) contained < 5.0 ng/ml. 
Koncentracija retapamulina je bila merljiva v 46 % (36/79) vzorcev (razpon: od 0,52 do 177,3 ng/ml), a je bila v večini teh vzorcev (27/36, 75 %) < 5,0 ng/ml.
In studies in impetigo and in two studies of secondarily infected open wounds (SIOW), clinical success rates were high for retapamulin in patients with mupirocin-resistant S. aureus (100%: 11/11) or fusidic acid-resistant S. aureus (96.7%: 29/30). 
V študijah uporabe pri impetigu in v dveh študijah uporabe pri sekundarnih okužbah odprtih ran so bili deleži klinične uspešnosti retapamulina visoki, tako pri bolnikih s proti mupirocinu odpornimi sevi S. aureusa (100 %: 11/11), kot pri bolnikih s proti fusidinski kislini odpornimi sevi S. aureusa
The effect of concurrent application of retapamulin and other topical medicinal products to the same area of skin has not been studied, and is not recommended. 
Učinka sočasne uporabe retapamulina in drugih zdravil za lokalno zdravljenje na istem predelu kože niso raziskovali.
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infection is questionable. 
Če so podatki o lokalni prevalenci odpornosti takšni, da je vprašljiva koristnost zdravila pri vsaj eni vrsti okužbe, je treba pridobiti ekspertno mnenje.
5 g, 10 g and 15 g aluminium tubes with a plastic screw cap. Carton of 1 tube. 
5 g, 10 g in 15 g aluminijaste tube s plastično navojno zaporko.
Clinical Response at Follow-up (day 12-14), by Analysis population Difference in success rates (%) 
Klinični odziv med spremljanjem (od 12. do 14. dneva) glede na analizirano populacijo Placebo
Altargo is for use on the skin only. 
Zdravilo Altargo je namenjeno izključno za uporabo na koži.
No treatment-related effects on male or female fertility have been shown in animal studies (see section 5.3). 
V študijah na živalih niso ugotovili z zdravljenjem povezanih vplivov na plodnost samcev ali samic (glejte poglavje 5.3).
S. aureus (all) MRSA 
S. aureus (vsi) MRSA $
Therefore caution is advised if retapamulin 10 mg/g ointment is administered to children in this age group who are also receiving CYP3A4 inhibitors, as further increase in systemic exposure to retapamulin may occur upon CYP3A4 inhibition. 
Zato je treba retapamulin 10 mg /g mazilo previdno uporabljati pri otrocih v tej starostni skupini, ki dobivajo tudi zaviralce CYP3A4, ker se lahko po zavrtju CYP3A4 sistemska izpostavljenost
Of the samples that had measurable concentrations 90% had retapamulin concentrations less than 2.5 ng/ml. 
V 90 % vzorcev z merljivo koncentracijo je bila koncentracija retapamulina manjša od 2,5 ng/ml.
Simi: + 354 535 7000 
Vistor hf. Simi: + 354 535 7000
No pharmacokinetic data are available in patients with renal or hepatic impairment. 
Pri bolnikih z okvaro ledvic ali jeter farmakokinetični podatki niso na voljo.
0.5 g aluminium foil sachet. 
0,5 g vrečica iz aluminijaste folije.
S. pyogenes 
MRSA MSSA S. pyogenes
If you accidentally swallow Altargo 
Če ste zdravilo Altargo pomotoma pogoltnili
While the S. aureus epidemiological cut off value for retapamulin is 0.5 µg/ml, the clinical significance of isolates with elevated retapamulin MICs is unknown due to the potential for high local concentrations (20,000 µg/ml) of retapamulin on the skin. 
0,5 µg/ml, klinični pomen izolatov z večjimi MIC retapamulina pa zaradi možnih visokih lokalnih koncentracij (20.000 µg/ml) retapamulina na koži ni znan.
Any signs or symptoms of overdose, either topically or by accidental ingestion, should be treated 
Katerikoli znak ali simptom prevelikega odmerjanja, bodisi pri lokalni uporabi bodisi pri zaužitju, je treba zdraviti simptomatsko.
In children aged from 9 months to 2 years it is possible that higher plasma concentrations may occasionally occur during treatment with retapamulin 10 mg/g ointment compared to older children and adults. 
Mogoče je, da se pri otrocih od 9. meseca do 2. leta starosti med zdravljenjem z retapamulin 10 mg/g mazilom občasno pojavijo večje koncentracije v plazmi kot pri starejših otrocih in odraslih osebah.
95% CI (%) 
95-odstotni IZ
Care must be taken to avoid ingestion. 
Potrebna je previdnost, da ne pride do zaužitja.
A single retapamulin concentration (95.1 ng/ml) exceeded the highest concentration observed in patients aged 2-17 years (18.5 ng/ml). 
Ena sama koncentracija retapamulina (95,1 ng/ml) je presegla največjo koncentracijo, ugotovljeno pri bolnikih, starih od 2 do 17 let (18,5 ng/ml).
Four plasma retapamulin concentrations (26.9, 80.3, 174.3, and 177.3 ng/ml) exceeded the highest concentration observed in patients aged 2-17 years (18.5 ng/ml). 
Štiri koncentracije retapamulina v plazmi (26,9, 80,3, 174,3 in 177,3 ng/ml) so presegle največjo koncentracijo, ugotovljeno pri bolnikih, starih od 2 do 17 let (18,5 ng/ml).
Read all of this leaflet carefully before you start using this medicine because it contains 
Pred uporabo natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
The safety and efficacy of retapamulin ointment in infants less than nine months of age has not been established. 
Pri dojenčkih, mlajših od devet mesecev, varnosti in učinkovitosti retapamulina v obliki mazila niso dokazali.
Single plasma samples were obtained approximately 4-8 hours after the first application on days 3 or 4 from patients aged from 2 months to 2 years with impetigo or with secondarily infected traumatic lesions or dermatoses (note that retapamulin is not indicated for use in secondarily infected dermatoses). 
Bolnikom, starim od 2 meseca do 2 let, z impetigom ali sekundarno okuženimi travmatskimi lezijami ali dermatozami, so približno 4 do 8 ur po prvi uporabi 3. ali 4. dan vzeli en vzorec plazme (opomba: retapamulin ni indiciran za uporabo pri sekundarno okuženih dermatozah).
n/N Success rate 
n/N Delež uspešnosti
Retapamulin ointment contains butylated hydroxytoluene, which may cause local skin reaction (e.g. contact dermatitis), or irritation to the eyes and mucous membranes. 
Mazilo z retapamulinom vsebuje butilhidroksitoluen, ki lahko povzroči lokalne kožne reakcije (npr. kontaktni dermatitis) ali draženje oči in sluznic.
Retapamulin is not recommended for use in children aged less than 9 months. 
Retapamulina ni priporočljivo uporabljati pri otrocih, mlajših od 9 mesecev.
By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, partially block P-site interactions, and prevent normal formation of active 50S ribosomal subunits. 
deloma ovirajo interakcije P-mesta in preprečijo normalno formiranje aktivnih 50S ribosomskih podenot.
However, the maximum individual systemic exposure in humans following topical application of 10 mg/g ointment on 200 cm2 of abraded skin (Cmax= 22 ng/ml; AUC(0-24) = 238 ng.h/ml) was 660-fold lower than the retapamulin IC50 for Pgp inhibition. 
10 mg/g mazila na 200 cm velikem predelu poškodovane kože (Cmax = 22 ng/ml; AUC(024) = 238 ng.h/ml) 660-krat manjša od IC50 vrednosti retapamulina za zaviranje Pgp.
Retapamulin should not be used to treat infections known or thought likely to be due to MRSA. 
Retapamulin se ne sme uporabljati za zdravljenje okužb, ki so ali bi lahko bile posledica
Severe skin reactions or allergies (frequency not known) If you develop a severe skin reaction or an allergy: (e.g. severe itching or severe rash, swelling of the 
Če se vam pojavi huda kožna reakcija ali alergija (npr. hudo srbenje ali hud izpuščaj, oteklost obraza,
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR 5 g, 10 g, 15 g TUBE 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA 5 g, 10 g IN 15 g TUBO